Effect of subcutaneous treatment with human umbilical cord blood-derived multipotent stem cells on peripheral neuropathic pain in rats.
10.4196/kjpp.2017.21.2.153
- Author:
Min Ju LEE
1
;
Tae Gyoon YOON
;
Moonkyu KANG
;
Hyun Jeong KIM
;
Kyung Sun KANG
Author Information
1. Department of Dental Anesthesiology and Dental Research Institute, School of Dentistry, Seoul National University, Seoul 03080, Korea. dentane@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Cord blood stem cell transplantation;
Neuropathic pain;
Rat subcutaneous injection;
Tissue inhibitor of metalloproteinase 2
- MeSH:
Animals;
Cord Blood Stem Cell Transplantation;
Humans*;
Injections, Subcutaneous;
Multipotent Stem Cells*;
Nervous System;
Neuralgia*;
Rats*;
Spinal Cord;
Tissue Inhibitor of Metalloproteinase-2;
Umbilical Cord*
- From:The Korean Journal of Physiology and Pharmacology
2017;21(2):153-160
- CountryRepublic of Korea
- Language:English
-
Abstract:
In this study, we aim to determine the in vivo effect of human umbilical cord blood-derived multipotent stem cells (hUCB-MSCs) on neuropathic pain, using three, principal peripheral neuropathic pain models. Four weeks after hUCB-MSC transplantation, we observed significant antinociceptive effect in hUCB-MSC–transplanted rats compared to that in the vehicle-treated control. Spinal cord cells positive for c-fos, CGRP, p-ERK, p-p 38, MMP-9 and MMP 2 were significantly decreased in only CCI model of hUCB-MSCs-grafted rats, while spinal cord cells positive for CGRP, p-ERK and MMP-2 significantly decreased in SNL model of hUCB-MSCs-grafted rats and spinal cord cells positive for CGRP and MMP-2 significantly decreased in SNI model of hUCB-MSCs-grafted rats, compared to the control 4 weeks or 8weeks after transplantation (p<0.05). However, cells positive for TIMP-2, an endogenous tissue inhibitor of MMP-2, were significantly increased in SNL and SNI models of hUCB-MSCs-grafted rats. Taken together, subcutaneous injection of hUCB-MSCs may have an antinociceptive effect via modulation of pain signaling during pain signal processing within the nervous system, especially for CCI model. Thus, subcutaneous administration of hUCB-MSCs might be beneficial for improving those patients suffering from neuropathic pain by decreasing neuropathic pain activation factors, while increasing neuropathic pain inhibition factor.
